Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Larimar Therapeutics(US:LRMR) Globenewswire·2026-03-19 11:00Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label studyContinued alignment with FDA to consider the use of skin FXN to support BLA submission seeking accelerated approval following recent START pilot program meetingTopline open label study data to support BLA submission expected in Q2 2026Plan to initiate screening in global Phase 3 confirmatory study in Q2 2026, with dosing of first patie ...